Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 4425

When Intel established its Intel Foundry Services division in early 2021, it was clear that it needed the contract chipmaking unit to be on par with Samsung and Taiwan Semiconductor Manufacturing Co. in terms of scale as fabs and production nodes are getting costlier. The goal was ambitious from the start, and it looks like the company intends to be rather aggressive too as it plans to become the second largest foundry by 2030.

“Our ambition is to be the No. 2 foundry in the world by the end of the decade, and [we] expect to generate leading foundry margins,” said Randhir Thakur, the president of Intel Foundry Services, in an interview with Nikkei Asia.

Read more | >

Cancer research – and its impact on patient care – has made some significant strides in just the last 10 years. For example, the availability and affordability of sequencing genetic information has improved greatly – meaning researchers and doctors are now better able to get information about a person’s risk for certain cancers as well as what drugs might work best for cancer patients. Another major leap forward came with the approval of vaccines that help prevent infections from the human papilloma virus (HPV) that cause cervical cancers. Many other advances have occurred in the areas of targeted therapy, immunotherapy, and cancer screening technology.

Still, cancer remains a massive health problem that researchers across the United States and elsewhere are working tirelessly to solve. Many experts are hopeful that they can build on decades of learning and recent advances to move even more rapidly toward reducing the cancer burden.

We invited 10 American Cancer Society Research Professors to share their perspectives and predictions for how cancer research will evolve over the next 10 years – and what this might mean for patients. These 10 experts are among the very best in their field; the Society’s Research Professor grants are awards that go to a select group – researchers and doctors who have made seminal contributions that have changed the direction of basic, clinical, psychosocial, behavioral, health policy or epidemiologic cancer research.

Read more | >

The GeForce RTX 4,090 is an absolute monster of a graphics card, but the battle for the next generation of GPUs is only getting started. On Thursday, AMD revealed its own 4K gaming champion, and the Radeon RX 7,900 XTX and 7,900 XT aim to topple Nvidia’s goliath with help from a stash of smart tricks that could make David himself blush.

In addition to improved ray tracing capabilities, the addition of AI cores, and memory galore, these first RDNA 3-architecture GPUs are also the first graphics cards featuring a multi-die “chiplet” design, swiping inspiration from AMD’s epic Ryzen success.

Read more | >

Over the past couple of months, Starlink has branched out, offering its service in more ways than ever before. As more and more people sign up for its service, the network naturally gets a bit more strained and congested. Now it looks like Starlink is implementing a way to combat network congestion by creating a data cap.

According to The Verge, Starlink service will now have a data cap starting in December. Next month, residential customers will start off with a 1TB bucket of data that will be designated as “Priority Access.” Priority Access data will be used anytime the internet is accessed during the hours of 7 am to 11 pm. Once the data is depleted, users will encounter slower data speeds during peak hours. The bucket will be replenished at the top of every month, and customers will have the option to buy Priority Access data, but it will cost 25 cents per GB.

For the most part, this shouldn’t really affect many customers, as Starlink states that less than 10 percent of its users actually manage to hit this cap every month. In addition to a new data cap, the company will also be expanding its service to more parts of Alaska and also Canada, primarily focusing on the Northern areas. For areas in the region that aren’t yet covered, Starlink does have plans to expand to more areas in the first part of 2023.

Read more | >

On December 6–7, 2022, the Buck Institute for Research on Aging will be hosting the Longevity Summit 2022. Lifespan.io is pleased to announce that we are an official media partner for this upcoming conference.

The Summit will see many of the leading experts in the field coming together in the grounds of the architecturally distinct Buck Institute. It is being framed as a peer-to-peer learning experience aiming to unite longevity entrepreneurs, pharma and biotech companies, investors, researchers, and government organizations.

Here’s what the organizers had to say about the event:

Read more | >

Dr Brian Kennedy explains why verifying longevity interventions work is key and why the transition to human trials is so important.

Brian Kennedy is one of the busiest people in the longevity business, with fingers in many of the most interesting antiaging pies. He was at the Longevity Investors Conference recently, discussing some of the latest discoveries in longevity research and giving a longevity industry overview.

The Longevity Investors Conference (LIC) is the world’s leading and most private longevity-focused investors-only conference. Providing relevant insights into the fast-growing field of longevity, the conference also offers expert education and investment opportunities, as well as fostering excellent networking opportunities. It was our privilege to attend and talk to so many key opinion leaders.

Visit Longevity. Technology — https://bit.ly/3PwtH8Y

Continue reading “Dr Brian Kennedy — validating aging interventions and why rapamycin is the gold standard” | >

The lone volunteer in a unique study involving a gene-editing technique has died, and those behind the trial are now trying to figure out what killed him.

Terry Horgan, a 27-year-old who had Duchenne muscular dystrophy, died last month, according to Cure Rare Disease, a Connecticut-based nonprofit founded by his brother, Rich, to try and save him from the fatal condition.

Although little is known about how he died, his death occurred during one of the first studies to test a gene editing treatment built for one person. It’s raising questions about the overall prospect of such therapies, which have buoyed hopes among many families facing rare and devastating diseases.

Read more | >

Dr Charles Brenner on the longevity understanding disconnect, the best interventions for longevity, and the NR trials he’d like to see.

The Longevity Investors Conference is a key event for those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. The world’s leading and most private longevity-focused investors-only conference, LIC attracts some of the most prominent thought leaders.

One of those thought leaders is Charles Brenner, the biochemist whose work on nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, includes the discovery of nicotinamide riboside (NR) kinase pathway and the resulting tech that led to the development of NR as an NAD-booster.

As Eric Verdin did recently, Brenner is one for driving the longevity debate, even if it causes more than a few ripples, and in cautioning against overstating progress, he is a significant calibration point for our industry (Twitter wars, notwithstanding). We were able to grab a few moments with Brenner at LIC to find out more about his thoughts on the current state of play.

Continue reading “Dr Charles Brenner: longevity is not a simple engineering problem” | >